Clareo Health | An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
* Have failed to achieve the desired or optimal level of glycemic control despite utilizing appropriate, individualized insulin regimens
* Have A1C \<=9.0% within 3 months of study enrollment
* Are receiving ongoing diabetes care under the guidance of a Health Care Provider (HCP) trained in the use of SYMLIN
You may not be if
* Are poorly compliant with their current insulin regimen, as defined by their HCP
* Are poorly compliant with prescribed blood glucose self monitoring, as defined by their HCP
* Have experienced recurrent patient-ascertained severe hypoglycemia requiring assistance during the past 6 months
* Have hypoglycemia unawareness
* Have a confirmed diagnosis of gastroparesis
* Require the use of drugs that stimulate gastrointestinal motility
* Are female and pregnant or lactating and for whom the HCP determines the potential benefit does not justify the potential risk to the fetus or infant
* Have been treated with SYMLIN within 3 months prior to study start
